Remtin
Generic Name
Remtinex Hydrochloride
Manufacturer
MediLife Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| remtin 5 mg tablet | ৳ 10.00 | ৳ 100.00 |
Description
Overview of the medicine
Remtin 5 mg Tablet is a non-benzodiazepine anxiolytic medication used to treat generalized anxiety disorder (GAD). It helps to alleviate symptoms such as nervousness, tension, irritability, and worry without causing significant sedation or risk of dependence often associated with benzodiazepines.
Uses & Indications
Dosage
Adults
Initial dose: 5 mg two to three times daily. May be increased by 5 mg increments every 2-3 days as needed, up to a maximum of 60 mg/day in divided doses. Typical maintenance dose is 20-30 mg/day.
Elderly
No specific dose adjustment is generally required, but caution is advised due to potential age-related decrease in renal or hepatic function. Start with a lower dose (e.g., 5 mg twice daily) and titrate slowly.
Renal_impairment
Use with caution in severe renal impairment. Consider reduced dosage and monitor carefully. Not recommended for patients with creatinine clearance less than 20 mL/min.
How to Take
Remtin tablets should be taken orally, with or without food. Consistent administration (always with food or always without food) is recommended to avoid significant variability in absorption. Do not crush or chew the tablet.
Mechanism of Action
Remtinex is believed to exert its anxiolytic effects primarily through its partial agonist activity at serotonin 5-HT1A receptors in the brain. It also has a weak antagonistic effect on dopamine D2 receptors. Unlike benzodiazepines, it does not directly affect GABA-A receptors, leading to a different side effect profile and reduced risk of physical dependence.
Pharmacokinetics
Onset
Anxiolytic effects begin within 7-10 days, with full therapeutic effects often seen after 2-4 weeks of continuous therapy.
Excretion
Excreted primarily via the kidneys (40-60%) and feces (20-40%) within 24-48 hours.
Half life
Approximately 2-11 hours (parent compound and active metabolite).
Absorption
Rapidly absorbed from the gastrointestinal tract; however, extensive first-pass metabolism limits systemic bioavailability to about 4%. Peak plasma concentrations occur within 40-90 minutes.
Metabolism
Extensively metabolized in the liver, primarily by cytochrome P450 3A4 (CYP3A4) to several hydroxylated metabolites, one of which is active (1-pyrimidinylpiperazine, 1-PP).
Side Effects
Contraindications
- Hypersensitivity to Remtinex or any component of the formulation
- Concomitant use with MAO inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy
- Severe hepatic or renal impairment
Drug Interactions
MAO inhibitors (MAOIs)
Concomitant use is contraindicated due to the risk of severe hypertensive reactions.
CNS depressants (e.g., alcohol, benzodiazepines, hypnotics)
Although Remtinex does not potentiate CNS depression, caution is advised, especially during initial therapy, due to individual variability.
CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin)
May significantly decrease Remtinex plasma levels, reducing its efficacy. Dose adjustment may be necessary.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice)
May significantly increase Remtinex plasma levels, increasing the risk of adverse effects. Dose reduction may be necessary.
Storage
Store below 30°C in a dry place, away from light. Keep out of reach of children.
Overdose
Symptoms of overdose may include nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress. Treatment is symptomatic and supportive, including gastric lavage or activated charcoal if recent ingestion. Monitor vital signs.
Pregnancy & Lactation
Use in pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. It is not known whether Remtinex is excreted in human milk; caution is advised when administered to a nursing mother. Consult a doctor.
Side Effects
Contraindications
- Hypersensitivity to Remtinex or any component of the formulation
- Concomitant use with MAO inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy
- Severe hepatic or renal impairment
Drug Interactions
MAO inhibitors (MAOIs)
Concomitant use is contraindicated due to the risk of severe hypertensive reactions.
CNS depressants (e.g., alcohol, benzodiazepines, hypnotics)
Although Remtinex does not potentiate CNS depression, caution is advised, especially during initial therapy, due to individual variability.
CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin)
May significantly decrease Remtinex plasma levels, reducing its efficacy. Dose adjustment may be necessary.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice)
May significantly increase Remtinex plasma levels, increasing the risk of adverse effects. Dose reduction may be necessary.
Storage
Store below 30°C in a dry place, away from light. Keep out of reach of children.
Overdose
Symptoms of overdose may include nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress. Treatment is symptomatic and supportive, including gastric lavage or activated charcoal if recent ingestion. Monitor vital signs.
Pregnancy & Lactation
Use in pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. It is not known whether Remtinex is excreted in human milk; caution is advised when administered to a nursing mother. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from the date of manufacture
Availability
Available in all registered pharmacies
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Patent protected (expected expiration 2035)
Clinical Trials
Extensive phase III clinical trials demonstrated Remtinex's efficacy and safety in patients with Generalized Anxiety Disorder over placebo. Ongoing post-marketing surveillance continues to monitor long-term effects.
Lab Monitoring
- Baseline and periodic liver function tests (LFTs) in patients with hepatic impairment
- Renal function monitoring in patients with severe renal impairment
Doctor Notes
- Advise patients that full anxiolytic effect may take several weeks.
- Monitor for signs of serotonin syndrome if co-administered with other serotonergic agents.
Patient Guidelines
- Take the medication regularly as prescribed by your doctor.
- Do not stop taking Remtin abruptly without consulting your doctor, as withdrawal symptoms may occur.
- It may take several weeks to experience the full therapeutic effects of this medication.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Remtin may cause dizziness or drowsiness, especially during the initial phase of treatment. Patients should be cautioned about operating hazardous machinery or driving until they are reasonably certain that Remtinex does not adversely affect their ability to engage in such activities.
Lifestyle Advice
- Avoid alcohol and other CNS depressants during treatment.
- Practice stress-reduction techniques like meditation or yoga.
- Maintain a balanced diet and regular exercise routine.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.